Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
argenx SEARGX +0.05%78 Debt-to-Equity is 0.01 as of Jun. 2026, which is at its 10-year median of 0.01. GuruFocus rates ARGX with a GF Score™ of 78/100 and a GF Value™ of $1,461.02 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 958 Biotechnology companies, argenx SE ranks better than 99.9% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for argenx SE's Debt-to-Equity or its related term are showing as below:
ARGX'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.01 Max: 0.01
Current: 0.01
During the past 13 years, the highest Debt-to-Equity Ratio of argenx SE was 0.01. The lowest was 0.00. And the median was 0.01.
ARGX's Debt-to-Equity is ranked better than 99.9% of 958
companies
in the Biotechnology industry
Industry Median: 0.16
vs ARGX: 0.01
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
argenx SE Debt-to-Equity Related Terms
argenx SE Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for argenx SE's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ARGX vs VRTX, REGN, RVMD: Debt-to-Equity Comparison
For the Biotechnology subindustry, argenx SE's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
argenx SE Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, argenx SE's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where argenx SE's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
argenx SE (ARGX) has a Debt-to-Equity of 0.01 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on argenx SE and its competitors. This is near median its historical median of 0.01. According to the industry distribution chart, argenx SE ranks #1 out of 958 companies in the Biotechnology industry, placing it in the top 0.099999999999994%.
Is argenx SE's Debt-to-Equity too high?
argenx SE's current Debt-to-Equity of 0.01 is near median its 10-year median of 0.01. The Biotechnology industry median Debt-to-Equity is 0.16. argenx SE's value of 0.01 is 93.8% below this industry median. Based on the distribution chart, argenx SE ranks #1 out of 958 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, argenx SE has a GF Score™ of 78/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does argenx SE's Debt-to-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, argenx SE ranks #1 out of 958 companies for Debt-to-Equity. This places argenx SE in the top 0% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.16. argenx SE's value of 0.01 is 93.8% below this benchmark. While the company's 10-year median is 0.01 vs. the industry median of 0.16, argenx SE has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. argenx SE's current Debt-to-Equity of 0.01 is 93.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on argenx SE and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. argenx SE's current Debt-to-Equity is 0.01, which is near median its own 10-year median of 0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is argenx SE stock overvalued right now?
Based on GuruFocus' analysis, argenx SE (ARGX) is currently considered Modestly Undervalued. The stock's GF Value™ is $1,461.02, compared to a current price of $1,039.76 — trading 28.8% below its estimated fair value. The current Debt-to-Equity is 0.01, which is near median its 10-year median of 0.01 and 93.8% below the Biotechnology industry median of 0.16. argenx SE's overall GF Score™ is 78/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For argenx SE (ARGX), the current Debt-to-Equity is 0.01 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is argenx SE (ARGX) Overvalued in 2026?
Based on GuruFocus' analysis, argenx SE stock appears to be undervalued.
The current stock price of $1,039.76 is trading 28.8% below its estimated GF Value™ of $1,461.02.
GuruFocus considers argenx SE to be Modestly Undervalued.
Key valuation signals for ARGX:
Debt-to-Equity: 0.01 (near median its 10-year median of 0.01)
GF Value™: $1,461.02 vs. price of $1,039.76 (28.8% below fair value)
Industry Position: 93.8% below the Biotechnology median (#1 of 958)
No single metric tells the full story. See the ARGX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
78GF Score
Get the complete analysis for ARGX
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ARGX has been successfully added to your 
